NCT01191723View on ClinicalTrials.gov

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Healthy
Interventions
DRUG

MAP0004

3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol

DRUG

Inhaler Placebo

Placebo for Inhaler administered in Treatments A and C

DRUG

Moxifloxacin

400mg encapsulated tablet administered in Treatment A as per protocol

DRUG

Placebo Capsule

Placebo for Moxifloxacin administered in Treatment B and Treatment C

Trial Locations (1)

Unknown

Cetero Research, Fargo

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY

NCT01191723 - QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo | Biotech Hunter | Biotech Hunter